Literature DB >> 12971640

High [18F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing's syndrome.

Akiko Shimizu1, Noboru Oriuchi, Yoshito Tsushima, Tetsuya Higuchi, Jun Aoki, Keigo Endo.   

Abstract

A 48-year-old woman with left adrenal tumor, which showed increased uptake of [18F] 2-fluoro-2-deoxy-D-glucose (FDG) was presented. Her adrenal tumor was incidentally discovered, although she had no remarkable illness, and her blood pressure was normal. Hormonal examination including dexamethason suppression test and diurnal variation in serum cortisol level confirmed preclinical Cushing's syndrome. CT, MRI and 131I-adosterol scintigraphy showed findings consistent with adenoma. FDG-PET revealed that tumor had standardized uptake value of 4.8, which was higher than usual benign tumors. Histological diagnosis of the resected adrenal tumor was adrenocortical adenoma without evidence of malignancy. Although the current literature showed that adenomas in general did not exhibit increased FDG uptake, adenoma in the present case with subclinical Cushing's syndrome showed intense uptake of FDG, suggesting FDG-PET could evaluate hormonal function of an adrenocortical adenoma in a completely asymptomatic normocortisolism patient.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12971640     DOI: 10.1007/BF03006609

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  8 in total

Review 1.  Contemporary adrenal scintigraphy.

Authors:  Milton D Gross; Anca Avram; Lorraine M Fig; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-25       Impact factor: 9.236

Review 2.  False-positive FDG PET uptake--the role of PET/CT.

Authors:  Sandra J Rosenbaum; Thomas Lind; Gerald Antoch; Andreas Bockisch
Journal:  Eur Radiol       Date:  2005-12-17       Impact factor: 5.315

Review 3.  Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature.

Authors:  Asha Kandathil; Ka Kit Wong; Daniel J Wale; Maria Chiara Zatelli; Anna Margherita Maffione; Milton D Gross; Domenico Rubello
Journal:  Endocrine       Date:  2014-10-02       Impact factor: 3.633

4.  A case of synchronous presentation of primary non-small cell lung carcinoma and pheochromocytoma.

Authors:  Jung Wan Han; Cheol-Hong Kim; Juah Jang; Hun Gu Lee; Doo Cheol Chung; Jung Eun Choi; Kwangtaek Kim; Ah Leum Lim; Won Jun Song; Yong Keun Song; Heungjeong Woo; In Gyu Hyun; Mi Kyung Shin; Yong Seong Lee; Ho-Seung Shin
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-04-30

Review 5.  Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm.

Authors:  W Zachary Stone; David C Wymer; Benjamin K Canales
Journal:  J Endourol       Date:  2013-10-09       Impact factor: 2.942

6.  18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation.

Authors:  Catherine Ansquer; Sonia Scigliano; Eric Mirallié; David Taïeb; Laurent Brunaud; Fredéric Sebag; Christophe Leux; Delphine Drui; Benoît Dupas; Karine Renaudin; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-19       Impact factor: 9.236

7.  Diagnostic efficacy of 18F-FDG PET/CT in patients with adrenal incidentaloma.

Authors:  Gamze Akkuş; Isa Burak Güney; Fesih Ok; Mehtap Evran; Volkan Izol; Şeyda Erdoğan; Yıldırım Bayazıt; Murat Sert; Tamer Tetiker
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

8.  Utility of F-18 FDG-PET in detecting primary aldosteronism in patients with bilateral adrenal incidentalomas.

Authors:  Myung Kwan Ko; Chan Sung Park; Sung Soo Byun; Jung Min Hong; Mu Yeol Lee; Kyung Hoon Kim; Yang Won Na; Hye Jeong Choi; Il Sung Nam-Goong; Young Il Kim; Eun Sook Kim
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.